Press coverage about Cesca Therapeutics (NASDAQ:KOOL) has trended positive this week, according to Accern. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cesca Therapeutics earned a news impact score of 0.27 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.7892637793874 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Several research analysts have recently commented on KOOL shares. ValuEngine raised shares of Cesca Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 11th. Maxim Group reissued a “hold” rating on shares of Cesca Therapeutics in a research note on Friday, May 12th.

Cesca Therapeutics (NASDAQ:KOOL) opened at 3.34 on Tuesday. The stock has a 50 day moving average of $3.42 and a 200 day moving average of $3.15. Cesca Therapeutics has a 1-year low of $2.41 and a 1-year high of $4.92. The stock’s market cap is $33.07 million.

WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at

About Cesca Therapeutics

Cesca Therapeutics Inc is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.

Insider Buying and Selling by Quarter for Cesca Therapeutics (NASDAQ:KOOL)

Receive News & Ratings for Cesca Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.